This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This talk dives into the science of cardiovascular fitness, its profound impact on longevity, and how to train smarter without overcomplicating it. I delivered it at the Golden Age Health Summit on March 15, 2025, in Austin, TX. Key Takeaways: Why VO2 max is your longevity superpower How aerobic fitness declines with age—and what to do about it A simplified 3-zone training model: Easy (50-70% HR max), Moderate (70-85% HR max), and Hard (85-100% HR max) Practical tips to train effectively w
Implantation of an intra-aortic balloon pump (IABP) did not improve 60-day survival or bridge to heart replacement (HRT) therapies in patients with heart failure-cardiogenic shock (HF-CS) compared to standard care, according to a study presented during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in JACC. The trial was stopped by the Data Safety and Monitoring Board at the prespecified interim analysis due to futility.
BackgroundPostoperative blood glucose levels significantly impact outcomes in cardiac surgery patients undergoing extracorporeal circulation (ECC) auxiliary to open heart surgery. While hypoglycemia and hyperglycemia are known risk factors for adverse outcomes, the optimal glycemic range for patients undergoing ECC remains unclear. This research examined the relationship between blood glucose levels and 90-day mortality in this high-risk group.MethodsThe data for this research were obtained from
Clopidogrel monotherapy was found to be more effective than aspirin monotherapy in lowering risk of major adverse cardiac and cerebrovascular events among patients at high risk of recurrent ischemic events who completed a standard duration of dual antiplatelet therapy (DAPT) following PCI, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in The Lancet.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
BackgroundPediatric cardiomyopathies are rare but life-threatening conditions with high mortality. Limited data exists on their clinical features and risk factors, especially in Asian populations, highlighting the need for further research in this area.MethodsThis retrospective cohort study analyzed data from 212 pediatric patients diagnosed with hypertrophic cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), or restrictive phenotype hypertrophic cardiomyopathy (RP-HCM) at a single center i
PCI guided by a novel, artificial-intelligence-powered (AI) method of angiographic fractional flow reserve (FFR) assessment known as AngioFFR, which calculates FFR from a single-view angiogram of the coronary arteries, was noninferior to IVUS for outcomes in patients with significant stenosis, according to new research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in the The Lancet.
This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?
This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?
From a quiet beginning as an introvert in Brooklyn, NY, Jeffrey A. Towbin, MD, FACC, has evolved to be a renowned leader, researcher and clinician in pediatric cardiology. For his groundbreaking work in gene discovery and identification, growing three different programs as a pediatric cardiology chief and his development of three separate high-level cardiomyopathy, heart failure (HF) and transplant programs, Towbin received the ACC Lifetime Achievement Award during ACC.25 on Saturday during the
This is an interesting case for your students who want to delve into dysrhythmias with an eye on detail. It is also a good teaching case for discussing treatment options when the diagnosis may be uncertain or controversial. I will start the discussion by admitting that I am not an expert of electrophysiology or complex dysrhythmias. My approach has always been more clinical - how is this rhythm affecting the patient and what are the chances it will deteriorate?
This narrative review aims to evaluate strategies for reducing door-to-balloon (D2B) time in ST-elevation myocardial infarction (STEMI) patients, focusing on pre-hospital, in-hospital, and technological innovations, as well as addressing challenges to ensure sustainability. We reviewed recent literature from 2004 onward, examining various approaches to streamline STEMI care and improve D2B time.
BackgroundRecent studies have found that heart rate response is impaired in patients with type 2 diabetes. However, it remains unclear how chronotropic competence changes in these patients and which chronotropic index is more closely related to type 2 diabetes. This study aims to investigate the changes in chronotropic competence in type 2 diabetes and compares the association of two different chronotropic indices with type 2 diabetes.Patients and methodsPatients who underwent cardiopulmonary ex
This cross-sectional study uses the 2022 National Health Interview Survey to compare rates of cardiometabolic risk factors and cardiovascular diseases between rural and urban US adults and to evaluate the extent to which health care access, lifestyle factors, and social risk factors contribute to rural-urban differences.
When Elfriede Pahl, MD, FACC, completed medical school in 1983, Ronald Reagan was in his first term as president and few pediatric patients with heart failure (HF) reached an age to vote in elections. Today, as she delivers the Dan G. McNamara Keynote, Pahl will look back at the medical advances over the last four decades that have added decades to the lives of those children.
Nature Reviews Cardiology, Published online: 31 March 2025; doi:10.1038/s41569-025-01144-z Inhibition of factor XI has emerged as a promising strategy to mitigate bleeding while potentially preserving antithrombotic efficacy. In this Review, the authors comprehensively discuss the rationale, pharmacology, evidence and future directions for factor XI inhibitors across various clinical settings.
When Victor J. Dzau, MD, FACC, takes the stage today to deliver the Eugene Braunwald Keynote, it will mark a profound full-circle moment in his remarkable career. Titled "Science, Medicine & Society: A Brave New World," his address promises to be both a tribute to the legacy of Eugene Braunwald, MD, MACC, and a clear-eyed examination of future challenges and opportunities in cardiovascular medicine.
(MedPage Today) -- CHICAGO -- For people with heart failure (HF), the long-presumed benefits of fluid restriction did not pan out in the FRESH-UP randomized trial. Patients showed similar changes in their Kansas City Cardiomyopathy Questionnaire.
Limiting fluid intake may have no benefit for patients with heart failure (HF), according to findings from the FRESH-UP study presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in Nature Medicine.
The goal of the FRESH-UP trial was to assess the safety and effect of lifestyle advice of a liberal vs. a restrictive fluid regimen in patients with chronic HF in an outpatient setting.
Among young athletes, while overall survival after a sudden cardiac arrest (SCA) is improving, the likelihood of survival varies by race, and SCA is more likely to occur during practice than games, according to a study presented at ACC.25 in Chicago and simultaneously published in JACC.
The NOTIFY-LVH randomized clinical trial determines whether previously collected cardiovascular imaging data could be harnessed to improve the detection and treatment of hypertension through a centralized clinical support pathway.
Patients with severe aortic stenosis who were treated with either TAVR or surgery had comparable rates of all-cause mortality or disabling stroke at five years, according to research presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago and simultaneously published in JACC. Valve durability and performance were also excellent in both groups.
The goal of the ALPACA phase 2 trial was to assess the safety of lepodisiran in patients with higher lipoprotein(a) concentrations, determine the magnitude and duration of the reduction in lipoprotein(a) concentrations, and help inform the dose and dosing interval for a long-term phase 3 trial assessing cardiovascular outcomes, which is currently under way.
The novel extended-duration small interfering RNA lepodisiran reduced mean serum concentrations of lipoprotein(a) (Lp[a]) from 60 to 180 days after being administered subcutaneously, according to results presented from the ALPACA study during a Featured Clinical Research session at ACC.25 in Chicago and simultaneously published in the NEJM.
(MedPage Today) -- CHICAGO -- Routine use of devices to prevent cerebral emboli during transcatheter aortic valve implantation (TAVI) did not prevent strokes, a large randomized trial showed. Incidence of stroke within 72 hours after TAVI or.
A direct comparison of a pulse oximeter and the gold-standard measurement of oxygen saturation in arterial blood varied significantly between patients with darkly pigmented skin compared to lighter skin pigmentation, according to the EquiOx study presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago.
(MedPage Today) -- CHICAGO -- Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery for younger patients at low surgical risk, with the Evolut Low Risk trial now halfway to its goal of 10-year follow-up. In.
Among patients with aortic regurgitation (AR) undergoing TAVR with the Trilogy valve, the rate of mortality at one year was 8.1%, significantly lower than the prespecified goal of 25% to show noninferiority, according to a study presented during a Late-Breaking Clinical Trial session at ACC.25 in Chicago.
The goal of the ALIGN-AR trial was to evaluate the efficacy and safety of the JenaValve Trilogy transcatheter heart valve in patients with symptomatic, greater-than-moderate native aortic regurgitation who were deemed high risk for surgery by heart teams.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
104 
Let's personalize your content